KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) EPS (Weighted Average and Diluted): 2019-2024

Historic EPS (Weighted Average and Diluted) for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Dec 2024 value amounting to -$1.69.

  • Recursion Pharmaceuticals' EPS (Weighted Average and Diluted) fell 5.88% to -$0.36 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.84, marking a year-over-year decrease of 18.71%. This contributed to the annual value of -$1.69 for FY2024, which is 6.96% down from last year.
  • Recursion Pharmaceuticals' EPS (Weighted Average and Diluted) amounted to -$1.69 in FY2024, which was down 6.96% from -$1.58 recorded in FY2023.
  • Recursion Pharmaceuticals' 5-year EPS (Weighted Average and Diluted) high stood at -$1.36 for FY2022, and its period low was -$3.99 during FY2020.
  • Over the past 3 years, Recursion Pharmaceuticals' median EPS (Weighted Average and Diluted) value was -$1.58 (recorded in 2023), while the average stood at -$1.54.
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first plummeted by 39.02% in 2020, then soared by 62.66% in 2021.
  • Over the past 5 years, Recursion Pharmaceuticals' EPS (Weighted Average and Diluted) (Yearly) stood at -$3.99 in 2020, then skyrocketed by 62.66% to -$1.49 in 2021, then increased by 8.72% to -$1.36 in 2022, then declined by 16.18% to -$1.58 in 2023, then declined by 6.96% to -$1.69 in 2024.